Repurposing Monepantel in Oncology: New 2026 Mini-Review
A 2026 conceptual review highlights monepantel's emerging anticancer mechanisms, including mTOR inhibition and autophagy induction, based on preclinical evidence.
By Sanare Lab · August 10, 2026 · 4 min read
Key Takeaway
Monepantel (MPL), an amino-acetonitrile derivative anthelmintic used in livestock, has emerged as a promising candidate for drug repurposing in oncology. A 2026 mini-review in Biomedicine & Pharmacotherapy highlights that MPL inhibits the mTOR/p70S6K signaling axis, induces autophagy, disrupts cell-cycle progression, and enhances endoplasmic reticulum stress in mammalian cancer cells. These preclinical findings suggest potential anticancer benefits, though no human clinical trials have been conducted to date.
Drug repurposing — the practice of finding new therapeutic uses for existing medications — has gained significant attention in oncology. One of the most unexpected sources of repurposing candidates is the veterinary medicine cabinet. Monepantel (MPL), an amino-acetonitrile derivative anthelmintic widely used to treat nematode infections in sheep and cattle, is now being investigated for its anticancer properties. This article examines a 2026 conceptual mini-review published in Biomedicine & Pharmacotherapy that synthesizes the emerging preclinical evidence for monepantel as a repurposed anticancer agent.
Unlike its antiparasitic action, which depends on nematode-specific nicotinic acetylcholine receptors, monepantel appears to operate through entirely different mechanisms in mammalian cancer cells. For patients exploring repurposed drug protocols, understanding these mechanisms is essential. Our protocol dosing workspace provides tools to help evaluate dosing considerations for various repurposed compounds. Monepantel joins a growing family of antiparasitic drugs — including fenbendazole and ivermectin — that researchers are evaluating for anticancer potential.
What Is Monepantel and How Does It Work?
Monepantel is an amino-acetonitrile derivative (AAD) anthelmintic approved for veterinary use against gastrointestinal nematodes in livestock. Its antiparasitic mechanism relies on binding to nematode-specific nicotinic acetylcholine receptors, causing paralysis and death of the parasites. However, in mammalian cells, monepantel does not interact with these receptors and instead targets fundamentally different cellular pathways.
The 2026 mini-review by researchers in Biomedicine & Pharmacotherapy systematically catalogues the preclinical evidence for monepantel's anticancer activity. The review identifies several key mechanisms that have been observed in laboratory studies across multiple cancer cell lines.
Preclinical Anticancer Mechanisms
The 2026 review highlights four primary mechanisms through which monepantel exerts anticancer effects in preclinical models:
mTOR/p70S6K pathway inhibition. Monepantel suppresses the mechanistic target of rapamycin (mTOR) signaling axis, which regulates cell growth, proliferation, and survival. By inhibiting mTOR and its downstream effector p70S6K, monepantel reduces protein synthesis and slows cancer cell proliferation.
Autophagy induction. Monepantel triggers autophagic responses — a cellular recycling process that can lead to cancer cell death when pushed to excessive levels. This mechanism is distinct from apoptosis and may be particularly relevant in cancers resistant to conventional chemotherapy.
Cell-cycle disruption. Preclinical studies show that monepantel causes G1 phase arrest, preventing cancer cells from progressing through the cell division cycle. This cytostatic effect limits tumour growth without necessarily causing immediate cell death.
Endoplasmic reticulum stress enhancement. Monepantel increases stress on the endoplasmic reticulum (ER), an organelle responsible for protein folding and processing. Excessive ER stress can trigger the unfolded protein response, leading to cell death in cancer cells that already have high protein synthesis demands.
Synergy with Conventional Chemotherapy
A particularly promising finding from the 2026 review is monepantel's ability to enhance the efficacy of conventional chemotherapeutic agents. In preclinical combination studies, monepantel improved the anticancer effects of standard chemotherapy drugs while maintaining what the review authors describe as an exceptional safety profile. This synergy may arise from monepantel's ability to target pathways that confer chemotherapy resistance, such as mTOR-driven survival signals.
However, the review explicitly notes that all evidence is preclinical. No human clinical trials evaluating monepantel in cancer patients have been published as of 2026.
Safety Profile and Translational Outlook
Monepantel's established veterinary safety record provides some reassurance about its general tolerability, but this does not translate directly to human cancer therapy. The drug's pharmacokinetics in humans — absorption, distribution, metabolism, and excretion — remain largely uncharacterized. Dosing, formulation, and route of administration for anticancer use would require dedicated preclinical and early-phase clinical studies.
The 2026 review concludes that monepantel represents a conceptual repurposing candidate with a strong mechanistic rationale but insufficient evidence to support clinical use at this time. The authors call for further preclinical studies and, ultimately, well-designed clinical trials to evaluate monepantel's potential in human oncology.
Frequently Asked Questions
What is monepantel?
Monepantel is an amino-acetonitrile derivative anthelmintic used in veterinary medicine to treat nematode infections in livestock such as sheep and cattle. It is now being investigated as a potential repurposed anticancer agent based on preclinical laboratory studies.
Does monepantel have clinical evidence in cancer patients?
No. As of 2026, all evidence for monepantel's anticancer activity comes from preclinical studies in cell lines and animal models. No human clinical trials in cancer patients have been published.
How does monepantel differ from fenbendazole as a repurposed drug?
Monepantel is an amino-acetonitrile derivative, while fenbendazole is a benzimidazole. They target different cellular pathways — monepantel primarily inhibits mTOR/p70S6K signaling and induces autophagy, whereas fenbendazole is known for microtubule disruption and ferroptosis induction. Both are veterinary anthelmintics being investigated for anticancer potential, but they have distinct mechanistic profiles.
In Plain Terms
Monepantel is a livestock dewormer that scientists are now studying for potential cancer-fighting properties. In laboratory studies using cancer cells and animal models, it appears to slow cancer cell growth by disrupting the mTOR signaling pathway — a key regulator of cell survival and proliferation. It also triggers autophagy, a process where cells break down their own components, and increases stress on the endoplasmic reticulum, an organelle responsible for protein folding. These effects have been observed only in preclinical models, not in human cancer patients. There are no clinical trials yet, so monepantel remains an early-stage research candidate with no established human dosing or safety data for cancer treatment.
Shop Sanare Lab
Lab-tested products for patients researching repurposed antiparasitic compounds.
180 capsules — 99% purity, laboratory tested
180 capsules — 99% purity, laboratory tested
Disclaimer: Links are informational and do not constitute medical advice. Always consult a healthcare provider before using any supplement or medication.
References
- Repurposing monepantel in oncology: A conceptual mini-review of proposed mechanisms. Biomed Pharmacother. 2026;PMID: 42176570. PubMed
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. The information about monepantel is based on preclinical research and conceptual reviews. Always consult a qualified healthcare provider before considering any off-label medication use.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.